REGULATORY

• AMED Chief Eyes 20-30% Team Expansion by FY2029
  February 14, 2024

• Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
  February 14, 2024

• MHLW to Review Pig Kidney Transplant Plan Including Ethical Issues: Minister
  February 14, 2024

• Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
  February 14, 2024

• Active Pharma Slapped with Biz Improvement Order for Illicit API Production
  February 13, 2024

• MHLW Panel to Draw Up Report by Year-End towards Amendment of PMD Act
  February 13, 2024

• Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
  February 13, 2024

• Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
  February 13, 2024

• Japan to Allow Submissions without Japanese Data If All Requirements Met
  February 9, 2024

• FPMAJ Supports Generic Industry Consortia Concept but Frets Antitrust Issues
  February 9, 2024

• Health Minister Admits Antitrust Challenge in Generic Industry Revamp
  February 9, 2024

• Takeda’s Acquired Hemophilia A Drug Up for Panel Review on February 22
  February 9, 2024

• New Govt Forum Moots US-Level Trial Environment, Priority Review Vouchers
  February 9, 2024

• Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
  February 8, 2024

• Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
  February 7, 2024

• Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
  February 7, 2024

• Govt Eyes Boosted Manpower at AMED towards Next 5-Year Plan from FY2025
  February 7, 2024

• AMED Needs More Manpower to Fulfill Its Role as Funding Agency: President
  February 6, 2024

• Opdivo, Olumiant, Dupixent Now in Line for Label Expansions
  February 6, 2024

• CSL’s Hemophilia Gene Therapy to Get Orphan Tag in Japan
  February 6, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 56
• 57
• 58
• 59
• 60
• 61
• 62
• 63
• 64
• …
• Next ›
• 最終 »